SEC Comment Letter for Vaxart, Inc. (VXRT) (CIK 0000072444) (VXRT) — Mar 9, 2009

Vaxart, Inc. (VXRT) (CIK 0000072444)
Date: March 9, 2009 · CIK: 0000072444 · Accession: 0000000000-09-012073

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-04829

Date

March 9, 2009

Author

Not clearly detected

Form

UPLOAD

Company

Vaxart, Inc. (VXRT) (CIK 0000072444)

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 March 9, 2009 Dr. Raafat E.F. Fahim, Ph.D. President and Chief Executive Officer Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852 Re: Nabi Biopharmaceuticals Form 10-K for the Year Ended December 31, 2007 Filed February 28, 2008 File No. 000-04829

Dear Dr. Fahim: We have completed our review of your annual report on Form 10-K and have no further comments at this time.

Sincerely,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010                                                                                                   March 9, 2009   Dr. Raafat E.F. Fahim, Ph.D. President and Chief Executive Officer Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852
Re: Nabi Biopharmaceuticals
 Form 10-K for the Year Ended December 31, 2007  Filed February 28, 2008  File No. 000-04829

Dear Dr. Fahim:
  We have completed our review of your  annual report on Form 10-K and have no
further comments at this time.

Sincerely,

          J e f f r e y  P .  R i e d l e r          A s s i s t a n t  D i r e c t o r

SecProbe.io